Publications

Explore our publications to see our expertise in action:

• Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study. Miyamoto K, Miller RM, Voors-Pette C, Oosterhaven JAF et al. Clin Transl Sci. 2024 Nov;17(11):e70060. doi: 10.1111/cts.70060
  
• Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Großkopf J, Voors-Pette C et al. Clin Infect Dis. 2024 Oct 15;79(4):1074-1084. doi: 10.1093/cid/ciae364
  
• Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: Results from two randomized, placebo-controlled clinical trials Abbara A, Ufer M, Voors-Pette C et al. Fertil Steril. 2023 Nov 2:S0015-0282(23)01989-1. doi: 10.1016/j.fertnstert.2023.10.031
  
• A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5 France
  N, Rubino C, Courtney Safir M, Maurer M, Duong T, Singamsetty D, Abd-Elaziz K, Chou T, Sankaranarayanan S, Ettema M, Cosford R, Dogterom P, Liu Enchi, Barlow C. The American Collage of Clinical Pharmacology. 2023. May 16. DOI: 10.1002/cpdd.1256
  
• Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults. Boof ML, Géhin M, Voors-Pette C et al. Br J Clin Pharmacol. 2023 Sep 26. doi: 10.1111/bcp.15914
  
• First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects. Abd-Elaziz K, Voors-Pette C, Wang KL et al. Clin Drug Investig. 2021 Jan;41(1):65-76
  
• The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects Markus S. Mueller , Patricia N. Sidharta , Christine VoorsPette et al. Orphanet J Rare Dis. 2020 Oct 27;15(1):303
  
• Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel Schilling U, Dingemanse J, Voors-Pette C et al. Clin Transl Sci. 2020 Sep;13(5):886-890
  
• Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist ClazosentanJuif PE, Dingemanse J, Voors-Pette C, Ufer M. AAPS J. 2020 Aug 3;22(5):103
  
• Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation Lionel Renaud MSc, Kristell Lebozec MSc, Christine Voors‐Pette MD et al. The Journal of Clinical Pharmacology 2020, 60(9) 1198–1208
  
• Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab Voors-Pette C, Lebozec K, Dogterom P et al. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964
  
• Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan Juif PE, Voors-Pette C, Ufer M, Dogterom P, Dingemanse J. Clin Transl Sci (2019) 12, 440–444;
  
• Randomized controlled trial assessing a traditional Chinese medicine remedy in the treatment of primary dysmenorrhea Kennedy S, Jin X, Yu H, Zhong S, Magill P, van Vliet T, Kistemaker C, Voors C, Pasman W. Fertil Steril. 2006 Sep;86(3):762-4
  
• Abdominal obesity and expression of familial combined hyperlipidemia van der Kallen CJ, Voors-Pette C, de Bruin TW. Obes Res. 2004 Dec;12(12):2054-61
  
• Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipidemia, but not type 2 diabetes mellitus van der Kallen CJ, Voors-Pette C, Bouwman FG et al. Atherosclerosis. 2002 Oct;164(2):337-46
  
• Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity Voors-Pette C, de Bruin TW. Atherosclerosis. 2001 Aug;157(2):481-9. Erratum in: Atherosclerosis 2001 Nov;159(1):245
  
• Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass Keulen ET, Voors-Pette C, de Bruin TW. Am J Hypertens. 2001 Apr;14(4 Pt 1):357-63
  
• The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats Hamers FP, Pette C, Neijt JP, Gispen WH.Eur J Pharmacol. 1993 Mar 16;233(1):177-8
  
• Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766 Hamers FP, Pette C, Bravenboer B, Vecht CJ, Neijt JP, Gispen WH. Cancer Chemother Pharmacol. 1993;32(2):162-6